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The introduction of highly active antiretroviral therapy (HAART) in 1996 has transformed a lethal disease to a
chronic pathology with a dramatic decrease in mortality and morbidity of AIDS-related symptoms in infected
patients. However, HAART has not allowed the cure of HIV infection, the main obstacle to HIVeradication being
the existence of quiescent reservoirs. Several other problems have been encountered with HAART (such as side
effects, adherence to medication, emergence of resistance and cost of treatment), and these motivate the
search for new ways to treat these patients. Recent advances hold promise for the ultimate cure of HIV infec-
tion, which is the topic of this review. Besides these new strategies aiming to eliminate the virus, efforts must be
made to improve current HAART. We believe that the cure of HIV infection will not be attained in the short term
and that a strategy based on purging the reservoirs has to be associated with an aggressive HAART strategy.
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Introduction
Human immunodeﬁciency virus 1 (HIV-1), identiﬁed 28 years
ago,
1 remains a global health threat responsible for a worldwide
pandemic with an estimated 33 million people infected.
2 More
than 7000 new HIV infections occur each day, and the number
of newly diagnosed infections remains far greater than the
number of people (around 50%) who have access to highly
active antiretroviral therapy (HAART). Advances have been
made in treating AIDS since the introduction of HAART in 1996.
This has transformed a lethal disease into a chronic pathology,
with a dramatic decrease of mortality and morbidity of
AIDS-related symptoms in infected patients.
3,4
Why is achieving a cure important?
Todate,theonlywaytotreatpatientsinfectedwithHIVreliesona
combination of drugs that acts at different stages of the viral life
cycle, preventing the virus from replicating. These molecules
target four stages of the cycle: viral entry, reverse transcription
of the viral genome, integration into the genome of the host cell
and maturation of viral proteins. This therapy can reduce
plasma virus levels below detection limits (≤50 copies/mL).
However, with very sensitive but expensive and technically chal-
lenging methods, a residual viraemia is still detected in patients
onHAART.
5–8Moreover,HIVRNAtypicallyreturnstoameasurable
plasma level in less than 2 weeks when HAARTis interrupted, sug-
gesting that even long-term suppression of HIV-1 replication by
HAART fails to totally eliminate HIV-1. These two latter phenom-
enaaremainlyduetotheexistenceofHIVreservoirs.
6,9–13Theex-
istence of integrated latent viruses or virus replicating at a very
low level in different cellular reservoirs is an obstacle to the eradi-
cation of the virus, and thus the total recovery of patients, and
requires strict adherence to lifelong treatment.
14–21 In addition,
these cellular reservoirs are often found in tissue sanctuaries,
such as the brain, where drug penetration may be several
orders of magnitude lower than in other tissues.
16,18 Viral clear-
ance from other reservoirs, such as from chronically infected
macrophages,isalsodifﬁcultsincereversetranscriptaseinhibitors
are usually ineffective and protease inhibitors have signiﬁcantly
lower activities in these cells than in lymphocytes.
22,23 Moreover,
emergence of many side effects may require the cessation of
treatment.
24 Furthermore, the development of many types of re-
sistance, related to the extreme mutability of the virus and in part
to treatment interruptions, has been described in the litera-
ture.
25–28 Another major concern is related to non-AIDS events
and non-AIDS mortality in patients having a residual viraemia
and a normal CD4+ count, a situation also described in some
HIV non-progressors. Owing to the residual viraemia, patients
developchronicinﬂammationthatleadstoseveralcomplications,
for instance, cardiovascular disease, nephropathy, faster evolu-
tion of viral hepatitis and cancer.
29–33
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1063Last but not least, a major problem related to HAART is the
cost of the treatment. Even the cost associated with the
cheaper generic forms of the drugs far exceeds the abilities of
many resource-limited countries in providing treatment. The
cost of this treatment will be increasingly important in the
future, with an overall global budget requirement to address
this problem from today to 2031 being estimated at US$397–
727 billion.
34 Since, to date, no effective HIV-1 vaccine is avail-
able,
35–38 it appears crucial to improve HAART and to develop
new strategies to cure HIV.
39,40
Which cure is needed: a functional or a sterilizing cure?
A sterilizing cure requires the total eradication of all HIV-infected
cells, including quiescent reservoirs. On the other hand, a func-
tional cure aims to mimic a situation encountered in some
special patients called ‘elite controllers’ who are able to control
viral replication and have less than 50 copies/mL of the virus
without any treatment. Although a sterilizing cure would be
the most appropriate and desirable, it may be difﬁcult or impos-
sible to really achieve. Only one reported case, the German case,
is known in the literature that suggests a possible eradication of
the virus.
41 A functional cure appears more feasible since it
seems impossible to get rid of HIV from latent cells and from
sanctuaries. We have to keep in mind however that the chronic
inﬂammation described in patients under HAART has also been
described in some elite controllers who have presented with
residual viraemia and higher immune activation compared with
healthy patients.
42–44 It is very likely that these patients will
develop more non-AIDS events compared with those who are
uninfected or actually cured.
How might we achieve a cure?
The best scenario would be to eradicate the virus from all
infected cells. Even though this appears very difﬁcult, we
should be able to drastically decrease the HIV reservoirs by iden-
tifying and then eliminating them. Residual on-going viral repli-
cation, whatever its origin, also has to be reduced to preclude
non-AIDS events.
In this article we will discuss new strategies under investiga-
tion that aim to eradicate HIV from infected patients. First we
will discuss a recently described case that showed a possible
eradication of HIV following transplantation of CCR5-deﬁcient
haematopoietic stem cells. This strategy may open new
avenues to cure HIV-infected patients. We will also discuss
novel strategies based on purging reservoirs followed by aggres-
sive HAART. This approach has already been used in several clin-
ical trials. Finally, we believe that HAART has to be improved and/
or intensiﬁed; however, we have to keep in mind that HAART
alone will not allow for a cure.
The critical role of CCR5 in maintaining
HIV-1 infection
A proof of concept
A report of a German patient being transplanted with stem cells
from a donor who carried the D32 CCR5 mutation and then con-
trolled his HIV infection has highlighted the critical role of CCR5 in
maintaining HIV infection.
45 It is well known that HIV-1 enters
cells by using CD4 receptors and CCR5 or CXCR4 coreceptors
and persons homozygotic for a 32 bp deletion in the gene
coding for CCR5 are resistant to HIV-1 infection.
46,47 It is note-
worthy that the origin of the CCR5-D32-containing ancestral
haplotype is recent (estimated range of 275–1875 years) and
might be related to a historic strong selective event such as an
epidemic of a pathogen that, like HIV-1, utilizes CCR5. This hypo-
thetical epidemic has increased the frequency of this mutation in
ancestral Caucasian populations.
48 Hutter understood the signiﬁ-
cance of the CCR5 mutation and suggested that transplantation
of stem cells originating from a donor homozygotic for the mu-
tation could effectively eradicate the virus. After the relapse of
leukaemia in the German patient with HIV there was no other
choice but to transplant allogeneic stem cells to this person.
The patient, as suggested by Hutter, received D32 CCR5
mutant stem cells. Following the medical intervention, the
patient has stopped HAART and HIV RNA has remained below
1 copy/mL for now over 4 years. In a recent paper this group
showed evidence even for a possible cure of HIV-1 infection in
this patient. Indeed, they demonstrated reconstitution of both
circulating and mucosal CD4+ T cells that do not express CCR5
while the patient remained free of the virus. Moreover, they
also found evidence that long-lived cells such as macrophages
became D32 CCR5. Since these cells are reservoirs for the virus
along with CD4+ T memory cells, it appears that the size of
the viral reservoir has decreased. This result was unexpected
since the patient’s CD4+ memory cells are still susceptible to
productive infection by lymphotropic (CXCR4-tropic) HIV. The
combination of radiotherapy and chemotherapy has allowed
the eradication of long-lived reservoirs, which has prevented
HIV rebound during the process of immune reconstitution follow-
ing stem cell transplantation. Although this speciﬁc case is a real
success, stem cell transplantation as a general strategy to cure
infected patients is not yet feasible due to the high mortality
of this treatment (20%–30%). This report constitutes a proof
of concept and opens the development of new strategies
targeting the CCR5 coreceptor.
CCR5 gene therapy
Among new treatments, CCR5 gene therapy could be a potential
treatment to cure HIV (Figure 1). In preclinical trials,
HIV-1-infected mice engrafted with zinc ﬁnger nuclease
(ZFN)-modiﬁed CD4+ T cells had lower viral loads and higher
CD4+ T cell counts than mice engrafted with wild-type CD4+ T
cells, consistent with the potential to reconstitute immune func-
tion in individuals with HIV/AIDS by the maintenance of an HIV-
resistant CD4+ T cell population.
49,50 Preliminary results of two
Phase 1 clinical trials using this attractive approach were pre-
sented at the 2011 Conference on Retroviruses and Opportunistic
Infections (CROI).
51,52 Lalezari presented data on transformed
CD4+ T cells. The wild-type CD4+ T cells were obtained from
six patients who had been living with HIV infection for
.20 years. Participants chosen had continued low CD4+ T cell
counts (ranging from 200 to 500 cells/mm
3), despite receiving
antiretroviral therapy, which reduced HIV viral load to an un-
detectable level. Both studies showed a successful and tolerated
engraftment of the transformed CD4+ Tcells. At the Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
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six subjects having initially .450 CD4+ T cells/mm
3 under
HAART
53 were followed for 12 weeks after infusion of ex vivo
transformed CD4+ T cells. Only one patient in this clinical trial
became undetectable for the virus. However, this patient
entered the clinical study with one D32 CCR5 mutation. There-
fore a functional cure with this gene therapy was not attained.
As explained during this conference, only 5% of the total CD4+
T cells were transformed, in contrast to the 100% in the
German patient who beneﬁted from stem cell transplantation.
There is hope however that this small fraction of cells will rise
in the body, since it is expected that the CCR5+ cells infected
by HIV-1 will die over time. It is possible that CCR52 mutants
will be selected and will replace the normal CCR5+ cells, since
the release of virus from these CCR5+ cells will not be able to
infect the transfused population of CCR52 mutants. A much
longer follow-up is needed to conﬁrm these expectations.
The long-term control of HIV by the German patient who
received a transplant of CCR5-deﬁcient haematopoietic stem
cells holds promise for a real cure,
54 but due to its toxicity, it is
not a realistic one as claimed by Lewin and Rouzioux.
55 Further
investigations in order to understand the mechanism by which
HIV was eradicated have to be performed. It would also be inter-
esting to repeat this approach in other patients, which will help
us to make further conclusions.
56 It even raises questions such
as why there is no HIV rebound from long-lived viral reservoirs
1 3
4
5
6
2
Gene therapy : switch
to CCR5 Δ32
DNMT inhibitors.
HDACs inhibitors.
Lysine-speciﬁc histone methyl
transferase inhibitors.
Potential targets for
reactivation.
nonpermissive mutant
TNFa-mediated NFKB
activation.
TNFa-Receptor
CCR5
CD4
IKK
IKBα
IKBα
P
p50
p50
p65
p65
Release
Viral particle
Cytoplasm
HIV-1 promoter
CpG Islands
Me Me Me Me
CTIP2
Suv39h1
LSD1
HDAC2
HDAC1
3
Sp1
3meK9H3
3meK4H3
Set1
Ac
5
4
Nuc-1
Nucleus
COMPASS 6
2
1
Figure 1. Promising new approaches to cure patients of HIV-1: molecular mechanisms at the macrophage level. Beside increasing the pool of new
molecules and improving the currently used ones in HAART, new approaches are required to reach a full recovery from HIV-1 infection. To date, HAART
can only control and prevent viral replication, but fails to achieve total viral clearance. New potential strategies include virus eradication through gene
therapy and clearance of the viral reservoirs. The ﬁrst strategy derived from the observation of the D32 CCR5 bone marrow transplanted German
patient, who seems to be free of HIV-1 infection. Owing to the high risk associated with surgery and the impossibility of using this method in a
large number of patients, gene therapy could be a way to disrupt the CCR5-mediated infection in order to mimic the previous results of the
German patient (1). The second strategy relies on associating the current HAART with molecules activating the viral transcription and/or targeting
host proteins favouring HIV-1 latency. On the one hand, the early stage of viral replication requires the transcription activator NF-kB, thus
cytokines such as TNF-a may allow the recovery of full viral transcription in latent reservoirs (2). On the other hand, chromatin-modifying enzymes
have been associated with HIV-1 transcription extinction through ﬁne modiﬁcations of the epigenetic code on the viral promoter. Limiting DNA
methylation of the CpG islands (3), increasing activation marks, such as acetylation of histones from Nuc-1 (4), and/or avoiding marks associated
with heterochromatin, such as simultaneous trimethylation of lysine 4 and lysine 9 (5,6) of histone H3 in Nuc-1 may revert the latently infected
state back to productively infected macrophages. This figure appears in colour in the online version of JAC and in black and white in the print
version of JAC.
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JACproducing CXCR4-tropic viruses or what the role is of the trans-
plantation procedure itself
45,55 in the eradication of the virus.
The debate, regarding whether the treatment of the German
patient represents a sterilizing cure or not, is far from over.
57
Gene therapy (including CCR5 gene therapy) is indeed a very at-
tractive approach to cure HIV-1 infection, but it is not for imme-
diate use, even though considerable progress in gene delivery
has been made.
58,59 Moreover, the debate as to whether or not
this gene therapy will lead to a sterilizing cure is still open.
60
Purging viral reservoirs
The main drawback of HAART is that it is unable to purge the
virus from quiescent reservoirs, i.e. truly latent cells,
61–63 and/
or from cells with cryptic on-going HIV replication,
7,64,65 or
from sanctuaries such as the brain.
66–68 Resting memory
CD4+ T cells are the major cellular and the best characterized
reservoirs in the natural host.
6,7,69–71 The presence of latent pro-
viral HIV-1 DNA in this cell population has deﬁnitely been
proven.
69
Other reservoirs than resting CD4+ T cells have also been pro-
posed.
16,18–20 Genetic studies showed that during rebound vir-
aemia (due to HAART interruption) the virus could be detected
from reservoirs other than CD4+ T cells.
62,72,73 It has been pro-
posed that peripheral blood monocytes, dendritic cells and
macrophages in the lymph nodes and haematopoietic stem
cells in the bone marrow can be infected latently and therefore
contribute to viral persistence.
14–17,19,61,74 It is still debated
whether or not viral persistence in these latter reservoirs is due
to true latency or to a low-level on-going replication.
75,76
Deciphering the molecular mechanisms underlying HIV per-
sistence is a prerequisite to devise novel treatments aiming to
purge these reservoirs. Several recent reviews describe in more
detail the mechanisms of HIV persistence with implications for
the development of new therapeutic strategies.
18,20,40,77–79
Before using strategies that aim at purging the reservoir in com-
bination with an intensiﬁed HAART, we need: (i) to identify and
characterize the molecular actors involved in the persistence of
latency, which relies on the chromatin environment; and (ii) to
understand the mechanisms of reactivation in order to prevent it.
Persistence of latency
Once HIV-1 DNA has integrated into the host genome, and
latency has been established, maintenance of HIV-1 latency
depends on the chromatin environment. The chromatin organ-
ization of the HIV-1 promoter with precisely positioned nucleo-
somes
80,81 has been well described. Nuc-1, a nucleosome
located immediately downstream of the transcription initiation
site, impedes long terminal repeat (LTR) activity. Epigenetic mod-
iﬁcations and disruption of Nuc-1 are a prerequisite of activation
of LTR-driven transcription and viral expression.
82 It was recently
found that recruitment of deacetylases and methylases on the
LTR was associated with epigenetic modiﬁcations (deacetylation
of H3K9 followed by H3K9 trimethylation and recruitment of HP1
proteins) in CD4+ T cells. In these experiments, the methylase
Suv39H1 and the HP1g proteins were knocked down by small
interfering RNA (siRNA). The depletion of these factors increased
the level of HIV-1 expression.
83
Epigenetic modiﬁcations of the LTR have also been described
in microglial cells, the CNS-resident macrophages. These cells are
major targets for HIV-1 and constitute latently infected cellular
reservoirs in the brain.
84 Previous work from our laboratory has
shown that a COUP-TF interacting protein 2 (CTIP2), a recently
cloned transcriptional repressor that can associate with
members of the COUP-TF family,
85 inhibits HIV-1 replication in
human microglial cells.
86,87 Subsequently we showed that
CTIP2 inhibited HIV-1 gene transcription in these cells by recruit-
ing a chromatin-modifying complex.
88 As demonstrated in T
lymphocytes, our work suggests a concomitant recruitment of
histone deacetylases HDAC1, HDAC2 and methylase SUV39H1
to the viral promoter by CTIP2. Ordered histone modiﬁcations
would allow HP1 binding, heterochromatin formation and, as a
consequence, HIV silencing. The heterochromatin formation
at the HIV-1 promoter has been linked to post-integration
latency, and this suggests that transcriptional repressors such
as CTIP2 are involved in the establishment and maintenance of
viral persistence and post-integration latency in the brain.
The corepressor CTIP2 has an even more pleiotropic action by
regulating the expression of genes of infected cells. Recruited to
the cellular cyclin-dependent kinase inhibitor CDKN1A/p21
waf
(p21) promoter, CTIP2 silences p21 gene transcription by indu-
cing epigenetic modiﬁcations, as described above, for the
HIV-1 promoter. This effect indirectly favours HIV-1 latency
since activation of the p21 gene stimulates viral expression in
macrophages.
89 Moreover, CTIP2 counteracts HIV-1 Vpr, which
is required for p21 expression. We suggest that all these factors
contribute together to HIV-1 transcriptional latency in microglial
cells.
90 The picture regarding the importance of p21 in the replica-
tive cycle of HIV-1 is far more complicated since p21 has been
described as a restriction factor in macrophages and in resting
CD4 T cells.
91,92 The protein p21 might have different effects
on HIV-1 infection of macrophages depending on the targeted
viral life cycle step, and therefore on the time since infection.
93
We have also identiﬁed a new actor involved in the mainten-
ance of HIV-1 latency in microglial cells, the lysine-speciﬁc
demethylase (LSD1).
94 We notably showed that LSD1 repressed
HIV-1 transcription and viral expression in a synergistic manner
with CTIP2 and reported that recruitment of LSD1 at the HIV-1
proximal promoter is associated with both H3K4me3 and
H3K9me3 epigenetic marks. Association of both H3K4me3 and
H3K9me3 epigenetic marks with LSD1 recruitment may thus
constitute a new level of eukaryotic gene regulation. These
observations are consistent with the discovery that H3K4 methy-
lation at certain chromatin loci may prevent gene expression.
95
Interestingly, such a gene repression linked to H3K4me3 has
been proposed to prevent the expression of cryptic promo-
ters.
95,96 This is strengthened by the ﬁnding that HIV-1 preferen-
tially integrates into active genes and therefore could be
considered as a cryptic gene.
Surprisingly, LSD1 has been associated with activation of HIV
transcription in CD4+ Tcells through demethylation of K51 Tat.
97
However, in microglial cells the mechanisms underlying
LSD1-mediated increase of H3K4 trimethylation is different and
might rely on the ability of LSD1 to anchor other factors at the
promoter rather than its own enzymatic activity. Indeed, H3K4
trimethylation was associated with the recruitment of LSD1,
hSET1 and WDR5 at the Sp1 binding sites of the HIV-1 LTR. More-
over, reactivation of HIV-1 proviruses correlated with the release
Review
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reduced H3K4 trimethylation. In contrast to CD4+ T cells, LSD1
is involved in the maintenance of HIV-1 latency in microglial
cells by favouring a local heterochromatin structure. These two
studies reporting a dual role of LSD1 through different mechan-
isms in two main HIV-1 targets point to the complexity of HIV
latency and raise the question of how effective the use of inhibi-
tors of LSD1 would be for full HIV-1 reactivation. Indeed, target-
ing LSD1 for full reactivation in microglial cells might not work in
lymphocytes. Instead, in the latter cells an induction of HIV
latency is expected.
98 Further investigation of the epigenetic
regulation of HIV latency is therefore needed in order to design
efﬁcient drugs targeting viral reservoirs.
Another ﬁeld of interest is DNA methylation, which has been
involved in DNA silencing and latency.
99 It is now well established
that DNA CpG methylation plays an important role in maintaining
HIV-1 latency,
100,101 despite previous controversies.
102 Therefore
DNA methylase inhibitors, such as 5-azacytidine, could be useful
in strategies aiming to reactivate reservoirs. It is noteworthy that
only a few percent of the latent viruses are methylated on their
DNA, but these reservoirs of latent viruses are highly resistant to
reactivation. Achieving a cure would probably require the treat-
ment of many different types of latency simultaneously by a
combination therapy approach.
Preventing reactivation
Several mechanisms acting at the transcriptional and post-
transcriptional level are at work in order to preclude HIV reactiva-
tion in latent reservoirs. Affecting these mechanisms may open
new ways to purge reservoirs. Sequestration of nuclear factor
kB (NF-kB) in the cytoplasm of latent cells is one of these
mechanisms.
103 T cell activation with tumour necrosis factor a
(TNF-a) allows translocation to the nucleus of NF-kB, which
then binds to the LTR and activates the early phase (Tat inde-
pendent) virus transcription (Figure 1). Besides TNF-a, many
other factors have been involved in HIV reactivation, including
interleukins (IL) IL-1b, IL-2, IL-6, IL-7, interferon g (IFN-g) and
CD154,
104–109 and could be used to purge the reservoirs.
Among mechanisms acting at the post-transcriptional level,
regulation of the exportation of viral RNAs by the poly track
binding protein (PTB) seems to be important in memory CD4+
T cells.
110 Another important mechanism that acts at the post-
transcriptional level involves microRNAs (miRNAs). These are
single-stranded RNAs of 19–25 nucleotides involved in various
biological processes in eukaryotic cells.
111,112 miRNAs interact
with a complementary sequence in the 3′-untranscribed region
(UTR) of target mRNAs by partial sequence matching, which
leads either to mRNA degradation or, more often, to translational
inhibition.
112 miRNAs are involved in the regulation of virus ex-
pression as well.
113 Recently it was shown that miRNAs regulate
the expression of the histone acetyltransferase Tat cofactor PCAF
and HIV replication.
114 In a recent paper, Huang et al. reported
an enrichment of miRNAs in clusters, which has been observed
only in resting CD4+ T cells and not in active CD4+ T cells.
115
They found that several of the miRNA clusters inhibited HIV rep-
lication, and suggested that miRNAs contribute to HIV latency in
resting primary CD4+ T cells. They proposed to use speciﬁc
antagomirs (anti-miRNA antisense) raised against these miRNA
in order to reactivate latent CD4+ T cells.
116 However, as
discussed by Sun and Rossi, the use of antagomirs to reactivate
latently infected cells could be toxic for uninfected cells.
117 The
feasibility of using miRNAs for HIV treatment is premature and
will need far more investigation.
Implications for therapies based on purging reservoirs
Original strategies based on the combination of a purge of the
reservoirs and intensifying HAART aim to eradicate the virus
from infected patients. Understanding the molecular mechan-
isms involved in latency will allow us to devise new strategies
that will facilitate the reactivation of all the reservoirs.
One strategy, known as ‘Immune Activation Therapy’, aims to
activate T cells
118–121 (Figure 1). Many physiological stimuli that
effectively activated T cells passed preclinical studies, but all
failed in clinical studies.
122 IL-7 held promise since this cytokine
is known to be essential for the maintenance of Tcell homeosta-
sis. Indeed, there are two subsets of memory T cells:
10 central
memory T cells (Tcm), which are maintained through T cell sur-
vival and low-level driven proliferation and can persist for
decades, and transitional memory T cells (Ttm), which persist,
in contrast, by homeostatic proliferation of infected cells and
could be reduced by using drugs preventing memory T cells
from dividing. Interestingly, an IL-7-driven proliferation of Ttm
cells can induce HIV expression from quiescent resting cells
without the death of the infected cells. This cytokine might
therefore be tested for its ability to reactivate expression of
latent HIV in order to purge this quiescent HIV reservoir.
123–125
A clinical trial using IL-7 in order to reduce the size of the
latent reservoir is currently running (ERAMUNE led by
C. Katlama; http://www.clinicaltrials.gov). Another profound
therapeutic implication, put forward by Chomont et al.,
10 is
that the size of the pool of CD4+ Tcm cells infected by HIV-1
should decrease with early treatment interventions.
126 Indeed,
these memory Tcm cells (and the CD8+ T cells) are thought to
be very important in the control of HIV infection, as shown in
elite controllers.
127,128 Since IL-7 is also involved in CD8+ T cell
function and T cell survival,
129–131 an early treatment that com-
bines HAART and IL-7 will certainly help patients to control their
HIV-1 infection (i.e. to get a functional cure), but might not allow
the eradication of the virus (i.e. to get a sterilizing cure).
A second strategy aiming to develop rational therapeutics
to ﬂush out HIV from latency relies on the knowledge of its
epigenetic regulation
132 (Figure 1). Several potential interesting
candidates have emerged, such as the histone deacetylase
(HDAC),
88 the histone methyltransferase,
83,88,133 DNA methyl-
transferases (DNMTs)
100,101 and proteins from the SWI/SNF
chromatin complexes.
134,135 A switch from latent to active tran-
scription has been described following treatment with several
HDAC inhibitors such as trichostatin, trapoxin, valproic acid and
sodium butyrate.
136–141 Valproic acid has been described to
effectively reactivate latent HIV reservoirs in a ﬁrst clinical
trial,
142,143 but two other clinical trials did not conﬁrm
this.
144,145 Failure of this ﬁrst clinical trial might be due to the
ineffectiveness of valproic acid in inhibiting HDAC3 activity in
CD4 T cells.
146 Indeed, several other HDACs, including HDAC3,
contribute to the repression of HIV-1 LTR expression.
147–149
Further investigations are needed using inhibitors against
newly identiﬁed epigenetic regulators of HIV latency such as
chaetocine (a histone methyl transferase inhibitor) or the DNA
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JACmethyltransferase inhibitors, including well-characterized
nucleotide analogue methylation inhibitors (5-azacytidine, 5--
aza-2′-deoxycytidine, 5-ﬂuoro-2′-deoxycytidine and zebulari-
dine) and non-nucleoside DNA methylation inhibitors (procaine,
procainamide, hydralazine and RG108).
78,150 Purging of latent
reservoirs could also be achieved by inhibiting regulatory pro-
cesses that prevent reactivation.
151 The p-TEFb activator HMBA
is a promising molecule currently under study. In pilot studies
it was able to reactivate latently infected cells and prevent
re-infection by down-regulating CD4 receptor expression.
152
There are several encouraging new directions in the purge of
reservoirs that are based on a combination therapy approach,
153
as already used in clinical trials to treat cancer.
154–156 Such an
approach has been found to be promising since the association
of an HDAC inhibitor or a DNA methylation inhibitor with prostra-
tin has a synergistic effect on the activation of HIV-1 expres-
sion.
101,157 The main beneﬁt of this synergistic effect is that we
might use drugs at suboptimal concentrations that would be suf-
ﬁcient to reactivate the virus but would have fewer side effects.
We believe that the most promising strategy to purge the reser-
voirs relies on combinations of such drugs, which would be able
to force viral gene expression at both the transcriptional and
post-transcriptional levels.
Finally, an alternative option has been proposed, which is not
based on virus reactivation, but on rendering the virus unable to
replicate in latent cells without inducing cell death.
158 This origin-
al ‘genome editing therapy’ is based on the recognition of essen-
tial sequences within HIV-1, such as the pol gene by zinc ﬁnger
endonuclease. Such a therapy has already been proposed to
disrupt the CCR5 gene, as described previously.
159
Improving HAART
Why is it important to improve HAART?
There are several reasons why HAARTshould be improved. One is
the existence of a residual viraemia in patients undergoing
HAART. The origin of this viraemia is still debated. There are
two theories explaining this residual viraemia: (i) long-lived
cells containing latent HIV provirus that can produce HIV at
low levels following reactivation; and (ii) low-level cryptic
on-going replication despite therapy. Latency is best described
as a lack of proviral gene expression. In contrast, on-going repli-
cation requires continuous viral gene expression without cyto-
pathic effects. Ineffective treatment in cells supporting
on-going replication could result from poor drug penetration
into sanctuaries such as the brain, where infected microglial
cells are located,
160 or from cell-to-cell transfer of the virus.
161
It is important to distinguish between these two theories, since
the therapeutic approaches they suggest are essentially differ-
ent. The theory of on-going replication suggests that drug resist-
ance to treatments might develop. In this case treatment
intensiﬁcation and the design of new anti HIV-1 molecules are
needed in the long term. On the other hand, if viruses are
released in bursts from stable reservoirs, multidrug resistance
does not develop, however, HAART alone is ineffective as well.
Several studies have looked at the efﬁciency of such intensiﬁca-
tion of HAART on residual viraemia and only one failed to reduce
it.
55,162 The second reason to improve HAART is related to the
‘shock and kill’ strategy discussed above. HAART by itself is not
able to achieve a cure, but is still needed (to kill) in association
with HIV reactivation from quiescent cells (to shock). Finally,
emergence of drug resistances, toxicity and compliance with
treatment are all obstacles to the current management of
HIV-1 infection and therefore need improvement of HAART.
163
How can we improve HAART?
Current management of HIV-1 treatment is based on seven
classes of antiretrovirals: nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhi-
bitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), entry/fusion inhibitors (EIs),
coreceptor inhibitors (CRIs) and integrase inhibitors (INIs).
164
The therapy of HIV-1-infected patients is based on a combin-
ation of three or more drugs from two or more classes.
165
We believe that new drugs should target other steps of the
HIV-1 cycle such as transcription, since there is no drug currently
available targeting this step. An increasing number of studies
suggest that inhibitors of cellular LTR-binding factors, such as
NF-kB and Sp1, repress LTR-driven transcription.
166–170 Recently
it has been shown that proteins of the DING family are good can-
didates to repress HIV-1 gene transcription.
171–173 Indeed, the
inhibitory effect of the human DING protein named HPBP
(human phosphate binding protein) on HIV-1 replication is very
strong,
173 even compared with other canonical drugs currently
used in HAART.
174 HPBP is also a potent anti-HIV-1 drug in per-
ipheral blood lymphocytes and in primary macrophages, which
is not true for several other anti-HIV-1 drugs. Very interestingly,
HPBP, which targets transcription, is as effective against
drug-resistant HIV strains as wild-type strains, highlighting the
potential therapeutic advantage of HPBP. Moreover, such drugs
could also be used to cope with chronic inﬂammation, which
leads to non-AIDS events.
175 We believe that this protein or its
derivatives are potentially interesting molecules and deserve
further study. As suggested for X-DING-CD4,
172 proteins belong-
ing to the DING protein family might have a role in the innate
response to infections, including HIV-1.
Finally, the use of nanotechnology involving structures
1–100 nm in size is an exciting approach since it will make it pos-
sible to reduce toxicity and facilitate treatment adherence.
176
Indeed, these nano-delivery systems will permit: (i) modulation
of drug release; (ii) protection of drugs from metabolism; and
(iii) speciﬁc targeting of infected cells, even those located in
sanctuaries. In corollary, this approach will allow improved bio-
availability and therefore reduce toxicity.
177–179 Among new
nanotechnology-based drug delivery systems are liposomes,
polymeric micelles, dendrimers and nanosuspensions. Potential
uses of these molecules have been reviewed.
176 This elegant
approach will surely improve gene therapy, immunotherapy,
vaccinology and microbicides.
180
When to start antiretroviral therapy?
Today there is no real consensus on when HAART should be
started. Until now, generally HAART was started when the
CD4+ T cell count was below 350 cells/mm
3, however, several
observations have pointed to a substantial beneﬁt in reduced
mortality if treatment is started at an earlier stage with no con-
sideration of CD4+ T cell count.
181,182 This is in agreement with
Review
1068the ﬁnding that starting treatment earlier reduced the size of the
latently infected reservoirs, as discussed above. Another major
concern with starting treatment earlier is that it should reduce
the outcome of non-AIDS events and non-AIDS mortality.
183
The cost of the treatment, drug toxicities and non-adherence
to the treatment by healthy patients has led some regulatory
organizations in Europe not to recommend initiation of HAART
in asymptomatic patients or patients having more than
350 CD4+ T cells/mm
3.
Conclusions
Are there reasons to be optimistic that a cure for HIV infection
may be achieved? From our point of view the answer is ‘yes’,
but this will not be achieved in the short term. Advances in
some ﬁelds are very exciting and offer new opportunities to
achieve a cure. For example, using gene therapy to confer HIV
resistance (including the CCR5 gene therapy) is a valuable
approach compared with chemotherapy, which has several
drawbacks, including toxicities, development of resistance and
cost. Several gene therapy trials are currently under way,
58 but
it is premature to make deﬁnitive conclusions regarding the
feasibility of these therapies. The ‘holy grail’ for clinicians will
be to achieve a sterilizing cure with total eradication of the
virus from the body, but we might only get a functional cure,
with few patients who control HIV-1 infection (the elite control-
lers). The major concern with a functional cure will be to drastic-
ally reduce the viraemia in order to prevent non-AIDS events. The
‘shock and kill’ strategy has also emerged as an exciting poten-
tial way to eliminate the virus. Here, too, we might be able to
achieve only a functional cure. The German case is the only
case where a possible sterilizing cure has occurred, incidentally
indicating a weakness of HIV. Today, however, we are limited
by a lack of technology to clearly demonstrate that this patient
is deﬁnitively cured. The war against this virus is far from over
and will need much more work. This review has focused on
current therapeutic strategies that could lead in the long term
to a cure. From a military point of view, this latter strategy con-
stitutes the ﬁrst front line. However, to win a war you usually
need to open a second front line, and this one is research
leading to the development of an HIV vaccine. Even if in practice
this approach is not yet working, efforts in this direction must be
made, but might require new avenues in HIV immunology
research.
36,184–186Undoubtedly research aiming at a therapeutic
cure will beneﬁt from research aiming to develop a vaccine, and
vice versa. Reasons to be optimistic come mainly from the inten-
sive efforts made in different ﬁelds of research, i.e. a multidiscip-
linary approach, including immunologists, virologists, molecular
biologists, clinicians, pharmacologists, chemists, physicists and
mathematicians, who have already opened new ways and elabo-
rated new concepts for therapies that are currently being tested
in clinical trials.
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